ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.

Diwakar Davar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.